Renee Webb

Duke Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Molecular Characterization of Hand Flora and Environmental Isolates in a Community Setting

Journal of Clinical Microbiology (2005)

Preeti Pancholi Mimi Healy Tracy Bittner Renee Webb Fan Wu

ABSTRACT We analyzed 69 bacterial isolates, comprising seven species of gram-negative bacterial rods and three species of coagulase-negative staphylococci, recovered from both the hands of caretakers and their environment in households sampled in upper Manhattan. Repetitive sequence-based PCR and dendrogram analysis were used to determine strain similarity. Greater than 25% of individual species of Acinetobacter , Enterobacter , and coagulase-negative staphylococci recovered from the hands and immediate environment within each household shared the same genotype. This study is the first to demonstrate the frequency of bacteria shared within community households. These strains may serve as potential reservoirs for either community- or hospital-acquired infections.

Flora

Dendrogram

Coagulase

Strain (injury)

10.1128/jcm.43.10.5202-5207.2005

Cite

Citations (21)

Molecular characterization of hand flora and environmental isolates in a community setting

Deep Blue (University of Michigan) (2005)

P. Pancholi Meghan Elisabeth Healy T. Bittner Renee Webb Fan Wu

Flora

Characterization

Source

Cite

Citations (1)

Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer

The Oncologist (2021)

John H. Strickler Christel Rushing Hope E. Uronis Michael A. Morse Donna Niedzwiecki

Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long-term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or without panitumumab in patients with metastatic colorectal cancer is warranted.The epidermal growth factor receptor (EGFR) antibody panitumumab is active in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), but nearly all patients experience resistance. MET amplification is a driver of panitumumab resistance. Cabozantinib is an inhibitor of multiple kinases, including vascular endothelial growth factor receptor 2 (VEGFR2) and c-MET, and may delay or reverse anti-EGFR resistance.In this phase Ib clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of cabozantinib and panitumumab. We then treated an expansion cohort to further describe the tolerability and clinical activity of the RP2D. Eligibility included patients with KRAS WT mCRC (later amended to include only RAS WT mCRC) who had received prior treatment with a fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.Twenty-five patients were enrolled and treated. The MTD/RP2D was cabozantinib 60 mg p.o. daily and panitumumab 6 mg/kg I.V. every 2 weeks. The objective response rate (ORR) was 16%. Median progression free survival (PFS) was 3.7 months (90% confidence interval [CI], 2.3-7.1). Median overall survival (OS) was 12.1 months (90% CI, 7.5-14.3). Five patients (20%) discontinued treatment due to toxicity, and 18 patients (72%) required a dose reduction of cabozantinib.The combination of cabozantinib and panitumumab has activity. Dose reductions of cabozantinib improve tolerability.

Panitumumab

Cabozantinib

10.1002/onco.13678

Cite

Citations (18)

MGMT Promoter Methylation Status Predicts Survival in Pediatric Glioblastoma

The FASEB Journal (2008)

Wenyong William Zhang Vidya Mehta Girard R. Courteau Jack M. Su Ching C. Lau

Pediatric glioblastoma (pGBM) represents 15% of pediatric brain tumors with a 3‐year survival rate of < 20%. Effective DNA repair is an important cellular mechanism for resistance to chemotherapy and radiation. The role of this mechanism in pGBM remains poorly understood. We evaluated the expression pattern of proteins (by immunohistochemistry) involved in the repair of DNA damage induced by alkylating agents, as well as, mismatch and base excision repairs including hMLH1, hMSH2 and PARP in fifteen pGBMs. MGMT promoter methylation was analyzed using methylation specific PCR and pyrosequencing. The relationship between DNA repair pathway alteration and survival was analyzed. MGMT promoter methylation was detected in 33% of tumors. Loss of hMLH1 and hMSH2 protein expression was seen in 47% and 53% of tumors, respectively. PARP expression was seen in 100% of pGBMs. hMLH1, hMSH2 and PARP expressions did not correlate with either event free survival or overall survival (p > 0.05). MGMT promoter methylation correlated significantly with better overall survival (p = 0.035). We conclude that MGMT promoter methylation status is a predictor of better survival in treated pGBM.

10.1096/fasebj.22.1_supplement.172.12

Cite

Citations (0)

1707Investigation of a Cluster of Mycobacterium interjectum Cases at a Tertiary Care Cancer Center

Open Forum Infectious Diseases (2014)

Ismini Kourouni Lauren Richardson Renee Webb Paula A. Revell Janet Eagan

Ismini Kourouni, MD 1, Lauren Richardson, BA 2, C. Renee Webb, BS, MT(ASCP) 4, Paula Revell, PhD 4, Janet Eagan, RN, MPH, CIC2, N. Esther Babady, PhD3, Yi-Wei Tang, MD, PhD 3, Mini Kamboj MD 2 1Department of Medicine, Mount Sinai Roosevelt Hospital Center, 1000 10th Ave, New York, NY 100192 Infectious Disease Service, Department of Medicine and 3 Microbiology Laboratory Service, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center [MSKCC], New York, NY 10065, Department of Pathology, Texas Children's Hospital, Houston, TX 77030

Center (category theory)

Tertiary care

10.1093/ofid/ofu052.1253

Cite

Citations (0)